Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23671)	3/24/2005 11:06:07 AM
From: nicewatch	Respond to of 48463

At this rate I'll be front and center for it when I visit Thailand. -gulp-

To: Henry Niman who wrote (23671)	3/28/2005 11:50:14 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48463

More outbreaks> Death Toll Rises in Angola from Hemorrhagic Virus By VOA News 28 March 2005 Reports from Angola say the death toll from an outbreak of the Marburg virus - a dangerous and deadly form of hemorrhagic fever similar to ebola - has risen to 122, the second-highest casualty toll ever attributed to the disease. Another 132 people suffering from symptoms of the Marburg virus have been hospitalized. Most cases of disease have been seen in the northern town of Uige, where the virus outbreak began in October. A small number of cases have been confirmed in Luanda. Authorities are concerned that international travelers passing through the Angolan capital could unknowingly spread the virus over a wider area. A health clinic in South Africa is urging travelers to avoid entering Angola for at least one week. Experts from the World Health Organization and the humanitarian group Doctors Without Borders are working in Angola on attempts to contain the virus (which causes severe diarrhea, vomiting and, in many cases, uncontrolled internal hemorrhaging that often leads to death). The Marburg virus was first identified in 1967, when it began spreading among laboratory workers in Europe who were working with monkeys. The worst previous outbreak occurred between 1998 and 2000 in what is now the Democratic Republic of Congo, 123 people died.

To: Henry Niman who wrote (23671)	9/19/2005 6:01:44 PM
From: xcr600	Respond to of 48463

I know you track the bird flu quite a bit.. ever heard of these guys?? UK's PowerMed joins race for bird-flu vaccine REUTERS 4:01 p.m. July 31, 2005 LONDON – Britain's privately owned PowderMed said on Monday it had developed a DNA-based vaccine against bird flu which could be produced quickly and in large quantities in the event of a pandemic. The British biotech firm's experimental vaccine, which is expected to enter clinical trials by the middle of next year, is further away from the market than rival shots against the H5N1 avian flu strain. But Chief Executive Clive Dix believes it may have a big advantage because it is not produced laboriously in chicken eggs, like conventional flu shots, and only tiny quantities will be needed to vaccinate large numbers of people. Industry analysts, however, said the novel DNA-based approach to vaccination was still largely untested and would face close scrutiny from healthcare regulators. "We're probably six months behind but we are in a unique position because we could produce enough vaccine in the first three months of pandemic to vaccinate everybody," he said. "Just 1.2 kg of vaccine DNA would be sufficient to vaccinate the entire population of the U.S. twice over." PowderMed's vaccine is produced by cloning a gene from the current circulating bird flu strain and slotting it into an existing DNA backbone vaccine. This "plug and play" system would enable the group to rapidly adapt the vaccine to include relevant DNA if a new and more dangerous strain develops, Dix said. Public health experts fear the avian flu virus could mutate and develop the ability to spread easily from person to person, potentially killing millions in a flu pandemic. So far, the H5N1 flu strain has killed more than 50 people in Asia, including in Vietnam, Thailand and Cambodia, and most recently Indonesia. The governments of the United States, Britain, France, Canada and Australia have all recently announced plans to stockpile H5N1 vaccine, and a number of companies are working to make a suitable product. Sanofi-Aventis SA is thought to be furthest ahead in the race but other Western vaccine groups are also busy in the area, along with companies in China and Vietnam. PowderMed was created via a management buyout last year after U.S. vaccine maker Chiron Corp acquired Britain's PowderJect Pharmaceuticals, the company which previously owned its powder-based DNA vaccine technology. Dix told Reuters that PowderMed was looking to return to the public market via an initial public offering at some stage, but probably not before 2007. Find this article at: signonsandiego.com